What is the address of Asterion Therapeutics?

The registered office of Asterion Therapeutics is located at Schaarbeekstraat(MEL) 20D box 1, 9120 Beveren-Kruibeke-Zwijndrecht.

Is Asterion Therapeutics still active?

Yes. According to the CBE (31 October 2026) Asterion Therapeutics is active, legal situation “Normale toestand”, started on 7 December 2018.

Is Asterion Therapeutics registered on Peppol?

Yes, Asterion Therapeutics is registered on the Peppol network with ID 0208:0715602553.

What is the enterprise number of Asterion Therapeutics?

The enterprise number of Asterion Therapeutics is BE0715602553.

When was Asterion Therapeutics founded?

Asterion Therapeutics was founded on 7 December 2018.

Who are the directors of Asterion Therapeutics?

According to the 2025 annual accounts, the directors of Asterion Therapeutics are: James Troch.

Is Asterion Therapeutics a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 7 December 2018; 2 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did Asterion Therapeutics make in 2025?

Asterion Therapeutics recorded a loss after taxes of € 95,406 in financial year 2025.

What is the revenue of Asterion Therapeutics?

As a small company, Asterion Therapeutics is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € -15,448.

Asterion Therapeutics (Private Limited) - BE0715602553

Q: What does Asterion Therapeutics do?

Asterion Therapeutics is registered with the CBE as active in: Vervaardiging van overige farmaceutische producten. Private Limited, started on 7 December 2018, 1 establishment.

Dossier Asterion Therapeutics, printed on 31 October 2026 from databakkes.be/en/0715602553/asterion-therapeutics. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Negative equity NBB

More debt than assets in 2 of the last 2 fiscal years.
Two loss years in a row NBB

Negative result in 2021 and 2025.
Figures corrected NBB

Corrected annual account filed for 2025.

Financials

Financial year 2025

Asterion Therapeutics from Beveren-Kruibeke-Zwijndrecht, company number BE0715602553, closed financial year 2025 with a result of € -95,406 after tax. For that financial year Asterion Therapeutics recorded a gross margin of € -15,448 and equity of € -214,025. Compared with financial year 2021, the result moved from € -25,842 to € -95,406. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on October 1, 2026.

What it is worth Caution

€ -214,025

▼ € 128,855 vs 2021

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -95,406

▼ 269 % more loss than in 2021

Profit after tax over the fiscal year.

Cash in the bank

€ 151

▼ 67% vs 2021

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € -259,025.

People and assets in 2025

Full-time equivalents estimate The annual accounts report no full-time equivalents. A micro company with one active director is usually run by that person; this is an assumption, not a figure from the source.

≈ 1

No payroll staff. One director, so that person most likely runs the business.

Debts at end 2025

Bank debt

€ 161,531

▲ 80% vs 2021

Loans from banks and other lenders, long and short.

Owed to suppliers

€ 30,564

▼ 3% vs 2021

Supplier invoices still open on the last day of the fiscal year.

Key figures per fiscal year Download key figures (CSV)
	2021	2025	Change 2021 → 2025
Gross margin	€ -17,865 Gross margin 2021: € -17,865 First fiscal year in the series	€ -15,448 Gross margin 2025: € -15,448 ▲ € 2,417 vs 2021 (€ -17,865) Favourable step	▲ € 2,417
Profit after taxes	€ -25,842 Profit after taxes 2021: € -25,842 First fiscal year in the series	€ -95,406 Profit after taxes 2025: € -95,406 ▼ € 69,563 vs 2021 (€ -25,842) Unfavourable step	▼ € 69,563
Equity	€ -85,170 Equity 2021: € -85,170 First fiscal year in the series	€ -214,025 Equity 2025: € -214,025 ▼ € 128,855 vs 2021 (€ -85,170) Unfavourable step	▼ € 128,855
Total debts	€ 121,352 Total debts 2021: € 121,352 First fiscal year in the series	€ 197,489 Total debts 2025: € 197,489 ▲ 63% vs 2021 (€ 121,352) Unfavourable step	▲ 63%
Cash	€ 463 Cash 2021: € 463 First fiscal year in the series	€ 151 Cash 2025: € 151 ▼ 67% vs 2021 (€ 463) Unfavourable step	▼ 67%
Retained profit	€ -111,990 Retained profit 2021: € -111,990 First fiscal year in the series	€ -259,025 Retained profit 2025: € -259,025 ▼ € 147,035 vs 2021 (€ -111,990) Unfavourable step	▼ € 147,035
Bank debt	€ 89,511 Bank debt 2021: € 89,511 First fiscal year in the series	€ 161,531 Bank debt 2025: € 161,531 ▲ 80% vs 2021 (€ 89,511) Unfavourable step	▲ 80%
Balance sheet total	€ 36,181 Balance sheet total 2021: € 36,181 First fiscal year in the series	€ 58,464 Balance sheet total 2025: € 58,464 ▲ 62% vs 2021 (€ 36,181) Unchanged	▲ 62%

Key figures of Asterion Therapeutics, fiscal years 2021 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to Asterion Therapeutics?

What happened at Asterion Therapeutics in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Oct 1, 2026 Corrected annual accounts filed for financial year 2025. filed late Source: NBB ↗
Dec 7, 2018 New establishment in Beveren-Kruibeke-Zwijndrecht. KBO
Dec 7, 2018 Start of the company according to the CBE. KBO

In short

From € 25,842 loss in 2021 to € 95,406 loss in 2025.

Original PDFs at the National Bank ↗

Management

Perpetuum Ventures 49.5%

The stake of Perpetuum Ventures comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

Asterion Therapeutics

Behind Asterion Therapeutics is James Troch. The shares are held by Perpetuum Ventures (49.5%).

Directors

According to the 2025 annual accounts

James Troch

Director

Also active at: DIGITAL DARWIN, VENTURE CAMPUS, 247 Energy, Perpetuum Ventures, Perpetuum CropScience, Deep Medicine, 247 Alpha, d2 benelux +1 more

Shareholders

Perpetuum Ventures

49.5%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Schaarbeekstraat(MEL) 20D box 1

9120 Beveren-Kruibeke-Zwijndrecht

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

Perpetuum CropScience same network

€ -13,933 gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0715.602.553

VAT number

BE 0715.602.553

Registered office

Schaarbeekstraat(MEL) 20D bus 1, 9120 Beveren-Kruibeke-Zwijndrecht

Names & denominations

Asterion Therapeutics · Asterion

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

7 December 2018

Peppol

Active · Active since 15 Apr 2026

Activities · NACE

Vervaardiging van overige farmaceutische producten

Vervaardiging van parfums en toiletartikelen

Overige detailhandel in voedingsmiddelen, neg

Vervaardiging van andere voedingsmiddelen, neg

Detailhandel in cosmetica en toiletartikelen

Detailhandel in medische en orthopedische artikelen, muv corrigerende brillen, lenzen en zonnebrillen

Detailhandel in medische en orthopedische artikelen in gespecialiseerde winkels

Overige detailhandel in voedingsmiddelen in gespecialiseerde winkels, n.e.g.

View on CBE Public ↗ Annual accounts (NBB) ↗